Tobam Has $3.52 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Tobam lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 40.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,922 shares of the biotechnology company's stock after selling 19,968 shares during the quarter. Tobam's holdings in Sarepta Therapeutics were worth $3,517,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SRPT. Wellington Management Group LLP grew its position in shares of Sarepta Therapeutics by 32.3% in the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock valued at $340,527,000 after purchasing an additional 665,087 shares during the period. Erste Asset Management GmbH acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $79,425,000. Janus Henderson Group PLC boosted its stake in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock worth $544,408,000 after acquiring an additional 543,143 shares during the last quarter. Soros Fund Management LLC purchased a new stake in shares of Sarepta Therapeutics during the third quarter worth approximately $25,800,000. Finally, Swedbank AB acquired a new position in Sarepta Therapeutics in the 4th quarter valued at $16,706,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT traded down $2.31 on Tuesday, hitting $110.43. The stock had a trading volume of 372,585 shares, compared to its average volume of 804,769. The company's 50-day moving average is $120.82 and its two-hundred day moving average is $125.57. The stock has a market cap of $10.55 billion, a price-to-earnings ratio of 88.42 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on SRPT shares. Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. HC Wainwright reaffirmed a "sell" rating and set a $75.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, January 30th. Guggenheim increased their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Deutsche Bank Aktiengesellschaft assumed coverage on Sarepta Therapeutics in a report on Tuesday. They issued a "hold" rating and a $136.00 price objective on the stock. Finally, Piper Sandler reduced their target price on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $176.77.

Insiders Place Their Bets

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares in the company, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.